Jacobs & Co. CA Has $15.55 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Jacobs & Co. CA boosted its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 0.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,441 shares of the company’s stock after buying an additional 279 shares during the quarter. Zoetis makes up 1.6% of Jacobs & Co. CA’s holdings, making the stock its 14th biggest holding. Jacobs & Co. CA’s holdings in Zoetis were worth $15,550,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Cherry Creek Investment Advisors Inc. grew its holdings in Zoetis by 2.0% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares during the period. Grove Bank & Trust grew its stake in Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the period. Hancock Whitney Corp increased its holdings in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC lifted its stake in Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares during the period. Finally, Edge Capital Group LLC boosted its holdings in shares of Zoetis by 3.7% during the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock worth $310,000 after buying an additional 64 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $211.89.

Check Out Our Latest Analysis on ZTS

Zoetis Stock Performance

Shares of ZTS traded down $1.10 during trading hours on Friday, hitting $163.92. The company’s stock had a trading volume of 1,693,172 shares, compared to its average volume of 2,277,081. The business has a 50 day simple moving average of $172.08 and a two-hundred day simple moving average of $180.20. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $73.95 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business earned $1.36 EPS. Zoetis’s revenue was up 11.6% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is 37.59%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.